Whitehawk Therapeutics (WHWK) Net Income towards Common Stockholders (2018 - 2025)
Historic Net Income towards Common Stockholders for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$17.7 million.
- Whitehawk Therapeutics' Net Income towards Common Stockholders fell 4106.02% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.2 million, marking a year-over-year decrease of 6725.19%. This contributed to the annual value of -$63.7 million for FY2024, which is 315.37% up from last year.
- Per Whitehawk Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$17.7 million for Q3 2025, which was down 4106.02% from -$52.8 million recorded in Q2 2025.
- Whitehawk Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$1.5 million during Q2 2021, with a 5-year trough of -$87.1 million in Q3 2021.
- In the last 5 years, Whitehawk Therapeutics' Net Income towards Common Stockholders had a median value of -$16.0 million in 2021 and averaged -$20.3 million.
- Per our database at Business Quant, Whitehawk Therapeutics' Net Income towards Common Stockholders crashed by 291134.16% in 2021 and then surged by 8338.0% in 2022.
- Quarter analysis of 5 years shows Whitehawk Therapeutics' Net Income towards Common Stockholders stood at -$16.0 million in 2021, then increased by 12.99% to -$13.9 million in 2022, then decreased by 16.93% to -$16.3 million in 2023, then decreased by 12.32% to -$18.3 million in 2024, then increased by 3.16% to -$17.7 million in 2025.
- Its Net Income towards Common Stockholders was -$17.7 million in Q3 2025, compared to -$52.8 million in Q2 2025 and -$14.4 million in Q1 2025.